GIA® vs. Cambridge Cognition (CANTAB)
Research-grade computerized test batteries and point-of-care conversational screening were built for two different rooms.
Cambridge Cognition offers CANTAB, a suite of computerized neuropsychological tests used heavily in research and clinical trials. Patients complete touch-based cognitive tasks that measure domains such as memory, attention, and executive function. Cambridge Cognition also acquired Winterlight Labs, adding speech-biomarker analysis to its portfolio. GIA® by Scienza Health screens for 46 conditions across cognitive, behavioral, and neurological health through a natural conversation lasting 40 seconds, using Voice AI, Computer Vision (436 visual data points), and 2,500+ Speech Biomarkers simultaneously. Where CANTAB provides research-grade cognitive batteries, GIA® provides conversational multimodal screening at the point of care.
How do they compare?
| Dimension | Cambridge Cognition (CANTAB) | GIA™ |
|---|---|---|
| Assessment method | Touch-based computerized cognitive tasks | Natural conversation with a Digital Human® |
| Condition coverage | Cognitive domains (behavioral and neurological separate) | 46 conditions: cognitive, behavioral, neurological |
| Primary setting | Research and clinical trials | Point of care: post-acute and long-term |
| Screening time | Varies by battery | 40 seconds |
| Patient interaction | Touch tasks on a device | Speech via video, voice, or landline |
| Speech biomarkers | Via Winterlight Labs acquisition | 2,500+ per conversation, plus computer vision |
| Clinical validation | Check vendor documentation | Peer-reviewed speech biomarker science across 19 studies |
Where cambridge cognition (cantab) falls short
A provider of computerized neuropsychological testing. CANTAB is a suite of touch-based cognitive tasks measuring domains such as memory, attention, and executive function, used heavily in research and clinical trials. Cambridge Cognition also acquired Winterlight Labs for speech-biomarker analysis.
- CANTAB batteries center on cognitive domains. Behavioral and neurological conditions such as depression, PTSD, and Parkinson’s typically require separate instruments
- Touch-based computerized tasks require patient interaction with a device interface
- Used heavily in research and clinical trials. Based on available information, point-of-care deployment in post-acute and long-term care is less established than research use
- Task-based batteries take longer than a brief conversation and can introduce test anxiety and practice effects
What GIA™ does differently
- Screens for 46 conditions across cognitive, behavioral, and neurological health in one conversation (25 live, 21 coming soon)
- 40 seconds of natural conversation. No test battery, no touch tasks. Results in under 2 minutes
- Multimodal: Voice AI, Computer Vision (436 visual data points), and 2,500+ Speech Biomarkers analyzed simultaneously
- Built for the point of care in post-acute and long-term settings, not primarily for research
- No practice effects. A conversation does not produce the repeated-exposure scoring artifacts of task batteries
- Zero clinical staff required during the screening. The clinician reviews results afterward
- Peer-reviewed speech biomarker science across 19 published studies. GIA® speaks 92 languages
CANTAB is a research-grade suite of computerized cognitive tests, strong in the settings it was built for. GIA® by Scienza Health screens for 46 conditions through conversation at the point of care, where a touch-based test battery is impractical to run across a census with no spare staff. Cambridge Cognition’s Winterlight acquisition brings speech biomarkers to its cognitive focus. GIA® combines speech biomarkers with computer vision and voice AI across cognitive, behavioral, and neurological categories in a single conversation. The clinician always reviews and decides.
Beyond the comparison
GIA® pairs every screening encounter with PDO — Proactive Decision Orders — a nightly EHR analysis layer that surfaces ranked clinical recommendations for physician review. No competing platform offers population-level decision support alongside point-of-care screening.
GIA® is trained on a dataset of 12.3M+ patients and 27B+ clinical records, validated across 19 peer-reviewed studies by independent researchers at academic medical centers.
Common questions
How is GIA® different from CANTAB?
CANTAB is a suite of touch-based computerized cognitive tasks used heavily in research and clinical trials, centered on cognitive domains. GIA® by Scienza Health screens for 46 conditions across cognitive, behavioral, and neurological health through a 40-second conversation using Voice AI, Computer Vision, and 2,500+ Speech Biomarkers, prepared for clinician review at the point of care.
Does Cambridge Cognition use speech biomarkers?
Cambridge Cognition acquired Winterlight Labs, which developed speech-biomarker analysis focused on cognitive markers. GIA® by Scienza Health analyzes 2,500+ speech biomarkers across cognitive, behavioral, and neurological conditions and combines them with Computer Vision and Voice AI in a single multimodal conversation.
Which is better for point-of-care screening in post-acute care?
Research-grade test batteries are demanding to run across a full census when staffing is short and patients cannot all interact with a touch interface. GIA® by Scienza Health requires only natural speech, works by video, voice, or landline, screens for 46 conditions in 40 seconds, and prepares results for clinician review. The clinician always reviews and decides.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.